Form 8-K - Current report:
SEC Accession No. 0001193125-25-003483
Filing Date
2025-01-08
Accepted
2025-01-08 16:01:44
Documents
13
Period of Report
2025-01-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d854734d8k.htm   iXBRL 8-K 32742
  Complete submission text file 0001193125-25-003483.txt   152698

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA syrs-20250106.xsd EX-101.SCH 2843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20250106_lab.xml EX-101.LAB 17234
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20250106_pre.xml EX-101.PRE 10807
15 EXTRACTED XBRL INSTANCE DOCUMENT d854734d8k_htm.xml XML 3499
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 25518520
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)